Search results
Author(s):
Barry Borlaug
Added:
4 months ago
HFSA 25 - Sex-specific outcomes of tirzepatide in obesity-related HFpEF showed that at baseline, women with HFpEF had more severe heart failure symptoms.Dr Barry Borlaug (Mayo Clinic, US) joins us to discuss a prespecified secondary analysis from the SUMMIT trial, examining sex-specific effects of tirzepatide in patients with heart failure with preserved ejection fraction and obesity.The SUMMIT…
View more
Author(s):
Harriette Van Spall
,
Tauben Averbuch
Added:
1 year ago
HFA 2024 — Dr Tauben Averbuch and Dr Harriette Van Spall (McMaster University, Hamilton, CA) discuss the findings from the PACT-HF trial. In this analysis of PACT-HF, investigators looked at long term sex-specific clinical outcomes and healthcare resource utilisation following hospitalisation for heart failure at 5 years.Findings shows that clinical outcomes and overall costs were similar between…
View more
HFSA 2025 Late-Breaking Science Collection
Author(s):
Nir Uriel
Added:
4 months ago
Video Series
Eva Gerdts
Research Area(s) / Expertise:
Job title: Chief of the Non-invasive Cardiac Imaging Unit
Author
Roxana Mehran
Research Area(s) / Expertise:
Job title: Professor of Medicine, Cardiology and Professor of Population Health Science and Policy
Author
Edina Cenko
Author
Laura Meems
Job title: Cardiologist
Author
F Aaysha Cader
Research Area(s) / Expertise:
Job title: Assistant Professor and Associate Consultant
Author
Andrea Russo
Job title: Director, Cardiac Electrophysiology and Arrythmia Service
Author
Author(s):
Harriette Van Spall
,
Mark Petrie
Added:
1 year ago
HFA 2024 — Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Mark Petrie (University of Glasgow, UK) for an insightful wrap up of the novel data presented at 2024's Heart Failure Congress.00:24 - STEP HFpEF Programme: Semaglutide 2.4 mg and NTproBNP in obesity-related HFpEF & Semaglutide therapy and diuretic use in obesity-related HFpEF02:20 - EMPACT-MI: The effect of…
View more
